Boston Scientific Corporation Q1 2026 Financial Report: Detailed Investor Update

Key Highlights

• Strong Revenue and Profit Growth: Boston Scientific Corporation reported robust performance for the first quarter ended March 31, 2026. Net income attributable to common stockholders was \$1,341 million for Q1 2026, which is a substantial increase from \$674 million in Q1 2025.
• Operating Income Surge: Operating income for the quarter was \$1,101 million in Q1 2026, compared to \$921 million in Q1 2025, indicating strong operational efficiency and margin expansion.
• Earnings Per Share (EPS): Basic EPS for Q1 2026 reached \$0.90, nearly doubling from \$0.46 in Q1 2025. Diluted EPS was \$0.90 in Q1 2026 and \$0.45 in Q1 2025.
• Comprehensive Income: Comprehensive income attributable to Boston Scientific stockholders soared to \$1,552 million in Q1 2026 from \$372 million in Q1 2025, reflecting strong performance and improved market conditions.
• Cash Position and Assets: The company ended Q1 2026 with \$1,453 million in cash and cash equivalents, though this is lower than the \$1,965 million reported at year-end 2025. Total assets increased to \$44,351 million from \$43,673 million at year-end 2025, demonstrating growth in the balance sheet.
• Stockholders’ Equity: Stockholders’ equity rose to \$25,864 million at the end of Q1 2026, up from \$24,233 million at year-end 2025.

Important Shareholder Information

• Outstanding Common Shares: As of April 29, 2026, the company had 1,486,355,000 shares of common stock outstanding.
• Stock-Based Compensation: During Q1 2026, Boston Scientific issued 3,293,986 shares under stock-based compensation plans, compared to 4,642,132 shares in Q1 2025. This could have a marginal dilutive effect but reflects continued investment in talent and alignment with shareholder interests.
• Treasury Stock: The company holds 263,289,848 shares in treasury, valued at \$2,251 million, unchanged from year-end 2025. This stability may indicate no major buyback or sales activity in the quarter.
• No Preferred Stock Issued: Boston Scientific has authorized 50 million shares of preferred stock, but none are issued, maintaining a pure common equity structure.

Potential Price-Sensitive Developments

• Profit and EPS Acceleration: The significant jump in net income and EPS is likely to be price sensitive, as it demonstrates strong business momentum and could lead to positive investor sentiment and valuation re-rating.
• Comprehensive Income and Currency/Derivative Impacts: The company reported notable changes in derivative financial instruments and foreign currency translation adjustments. For Q1 2026, derivative gains net of tax were \$79 million, while foreign currency translation adjustments net of tax were a loss of \$214 million. These may affect future earnings volatility and should be monitored by investors.
• Balance Sheet Growth: The increase in total assets and stockholders’ equity signals stronger financial health and capacity for future investment, acquisitions, or shareholder returns.
• Forward-Looking Statements & Risks: Boston Scientific cautioned investors regarding risks such as supply chain disruptions, cyber events, regulatory changes, geopolitical tensions, and currency fluctuations. New risks may emerge, and actual results could differ materially from projections.
• Commitments & Contingencies: The balance sheet notes that commitments and contingencies exist, though specific amounts are not disclosed. Investors should be aware of potential off-balance sheet risks.

Additional Details for Investors

• Regulatory Compliance: Boston Scientific confirms it has filed all required reports and submitted Interactive Data Files, maintaining its status as a large accelerated filer and not a shell company.
• Segment Reporting: The company’s reportable segment includes Latin America and Canada, among others, indicating geographic diversification.
• Stock Exchange Listing: The common stock trades under the symbol BSX on the New York Stock Exchange.

Outlook & Risks

Boston Scientific’s management reiterates that forward-looking statements are subject to risks including economic conditions, political and regulatory changes, supply chain disruptions, cybersecurity threats, and competitive pressures. Investors should monitor these factors, as they can materially affect future results and share price.

Conclusion

Boston Scientific’s Q1 2026 report demonstrates strong growth in revenue, profitability, and equity. The significant acceleration in net income and EPS, balanced by prudent management of equity and treasury stock, is likely to positively influence the share price. Investors should remain vigilant regarding potential risks and currency/derivative impacts, but the overall financial health and operational momentum are encouraging for shareholder value.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. The information is based on Boston Scientific Corporation’s Q1 2026 SEC filings and may be subject to future revisions or updates. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The author accepts no liability for actions taken based on this report.

View BOSTON SCIENTIFIC CORP Historical chart here